Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Abstract Background Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual...

Повний опис

Бібліографічні деталі

Автори:	Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-09-01
Серія:	Journal of Hematology & Oncology
Предмети:	Primary central nervous system lymphoma Phase IB trial Ibrutinib Lenalidomide
Онлайн доступ:	https://doi.org/10.1186/s13045-024-01606-w
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!